New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
15:20 EDTDVAXDynavax March volatility elevated at 197 into PDUFA
Dynavax March call option implied volatility is at 197, April is at 148, July is at 112; compared to its 26-week average of 114 according to Track Data, suggesting larger price movement into PDUFA Date for Heplisav on February 24.
News For DVAX From The Last 14 Days
Check below for free stories on DVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
06:08 EDTDVAXDynavax initiates Phase 3 study of HEPLISAV-B
Dynavax Technologies announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study, known as HBV-23, was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the FDA in February, 2013. HBV-23 will provide greater clarity regarding the safety profile of HEPLISAV-B by significantly expanding the overall database of vaccinated subjects. The study will also assess the immunogenicity of HEPLISAV-B in subjects for whom approved hepatitis B vaccines are less effective. Dynavax expects that all study subjects will be enrolled by the end of 2014 and all follow-up will be completed by 4Q15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use